Please login to the form below

Norway

This page shows the latest Norway news and features for those working in and with pharma, biotech and healthcare.

The study showed that the UK performed worse than Australia, Canada, Denmark, Ireland, New Zealand and Norway in terms of cancer survival rates. .

New efficacy data boosts Aimovig’s migraine market lead

The data will be presented at the European Academy of Neurology's (EAN) annual meeting in Oslo, Norway.
Resurgent Diurnal raises £5.4m for twin product filings

In March, Diurnal also signed its first partnership for Alkindi with Swedish group Anthrop Pharmaceuticals, which covers the commercialisation of the drug in Sweden, Norway, Denmark, Finland and Iceland, a
Brexit "having impact on EU drug development”

states, plus Iceland and Norway.
UK business: Brexit deadlock causing “frustration and anger”

as Norway Plus – which was another EFTA/EEA approach.
Business warning as talk of Brexit ‘No deal’ grows

as a ‘Norway’ style deal.

More from news
Approximately 1 fully matching, plus 124 partially matching documents found.

The case for a second Brexit referendum: “We need the informed consent of the people”

As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time.
The tipping point

National policy mandates to switch from the originator to biosimilars, as has been the case in Norway, have resulted in rapid and almost complete biosimilar market penetration.
Building a bright future

We have many examples where small molecule and biosimilars have improved uptake such as the case of infliximab in Norway, which was supported by the government that sponsored clinical trials showing
Pharma deals continue to slide

For example this month, Karo Pharma, Sweden acquired Weifa, Norway for $163m for product and territory complementarity.
2016: The year when deal-makers took stock?

product. (According to the journal Biosimilar Development the price of EPO in Norway was sold at an 83% discount from the original price.). ... The rate of uptake of biosimilars in Norway is exceptional, but the upward trend in other countries is still

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Gilead Sciences appoints general manager, Canada

Brysting was most recently general manager of Gilead Nordics, comprising the company's businesses in Sweden, Norway, Denmark, Finland and Iceland.
Targovax appoints chief financial officer

Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
Algeta execs join Targovax

Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.
Anker Lundemose appointed CEO of Bionor Pharma

The Norway-based biotech, which is focused on peptide-based vaccines for HIV, said Dr Lundemose will take over the role from March 1, when his predecessor Steen Krøyer becomes deputy
Matt Regan named AbbVie’s general manager in UK

Was formerly general manager of Abbott in Norway. AbbVie, the new independent biopharma spin-out from Abbott, has appointed Matt Regan as general manager of its UK business. ... Regan was formerly general manager for Abbott in Norway and will now oversee